Abbott has launched the FreeStyle Libre 3 Plus sensor, a discreet device to monitor glucose levels for diabetic patients. The sensor, which is the size of two stacked pennies, can be worn on the upper arm for up to 15 days and sends glucose data to a mobile app or handheld reader every minute. Abbott plans for future integration with automated insulin delivery systems. The company’s commitment to innovation in diabetes management is further demonstrated by acquiring Bigfoot Biomedical, which creates a “smart” insulin pen cap. Abbott’s FreeStyle Libre sales reached $5.3 billion in 2023, making it the most successful medical device in history.
Source link
Abbott Says Its Latest CGM Sensor Is Its Most Discreet Yet
